[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369764-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369764-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dysregulated-alternative-splicing-in-breast-cancer-subtypes-of-rif1-and-other-transcripts","Dysregulated Alternative Splicing in Breast Cancer Subtypes of RIF1 and Other Transcripts","","Genome instability drives cancer progression through mutations and disrupted genome maintenance involved in DNA replication and repair. Rap1 Interacting Factor 1 (RIF1) is critical for genome stability and cancer pathogenesis, expressed as two splice variants, RIF1-Long and RIF1-Short, with different capacities to buffer replication stress. The study compares RIF1 splicing in cancer cell lines and in TCGA matched normal and tumor samples, identifying subtype-specific exon exclusion patterns linked to clinical outcome.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dysregulated-alternative-splicing-in-breast-cancer-subtypes-of-rif1-and-other-transcripts/369764/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dysregulated-alternative-splicing-in-breast-cancer-subtypes-of-rif1-and-other-transcripts/369764.png","ImageObject",300,407,{"name":42,"@type":43},"Dipper","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What roles do RIF1-Long and RIF1-Short play in genome stability and replication stress?","Question",{"text":63,"@type":64},"RIF1 variants differ in their ability to protect cells from DNA replication stress, with RIF1-Long providing stronger replication stress resistance. The RIF1-Short form is linked to reduced protection under replication stress conditions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does RIF1 splicing differ across breast cancer subtypes?",{"text":68,"@type":64},"Luminal A, Luminal B, and HER2-enriched cancers tend to exclude RIF1 Exon 31, favoring RIF1-Short and correlating with poorer clinical outcomes. Basal breast cancer shows exon exclusion but does not consistently exclude RIF1 Exon 31.",{"name":70,"@type":61,"acceptedAnswer":71},"What dataset and sample design were used to evaluate RIF1 expression and splicing?",{"text":72,"@type":64},"The analysis uses matched normal and tumor data from The Cancer Genome Atlas (TCGA), alongside cancer cell line experiments under replication stress. This design supports comparison of differential expression and splicing patterns.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369764,1790794578,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nDysregulated Alternative Splicing in Breast Cancer Subtypes of RIF1 and Other Transcripts  \nEmma Parker, Laura Akintche, Alexandra Pyatnitskaya, Shin-ichiro Hiraga  and Anne D. Donaldson *  \nAcademic Editor: Yoshihito Kano  \nReceived: 24 June 2025  \nRevised: 16 July 2025  \nAccepted: 18 July 2025  \nPublished: 29 July 2025  \nCitation: Parker, E.; Akintche, L.; Pyatnitskaya, A.; Hiraga, S.-i.; Donaldson, A.D. Dysregulated Alternative Splicing in Breast Cancer Subtypes of RIF1 and Other Transcripts. Int. J. Mol. Sci. 2025, 26, 7308. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26157308  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nChromosome & Cellular Dynamics Section, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK  \n* Correspondence: [a.d.donaldson@abdn.ac.uk](a.d.donaldson@abdn.ac.uk)  \nAbstract  \nGenome instability is a hallmark of cancer, often driven by mutations and altered expression of genome maintenance factors involved in DNA replication and repair. Rap1 Interacting Factor 1 (RIF1) plays a crucial role in genome stability and is implicated in cancer pathogenesis. Cells express two RIF1 splice variants, RIF1-Long and RIF1-Short, which differ in their ability to protect cells from DNA replication stress. Here, we investigate differential expression and splicing of RIF1 in cancer cell lines following replication stress and in patients using matched normal and tumour data from The Cancer Genome Atlas (TCGA) . Overall RIF1 expression is altered in several cancer types, with increased transcript levels in colon and lung cancers. RIF1 also exhibits distinct splicing patterns, particularly in specific breast cancer subtypes. In Luminal A (LumA), Luminal B (LumB), and HER2-enriched breast cancers (HER2E), RIF1 Exon 31 tends to be excluded, favouring RIF1-Short expression and correlating with poorer clinical outcomes. These breast cancer subtypes also tend to exclude other short exons, suggesting length-dependent splicing dysregulation. Basal breast cancer also shows exon exclusion, but unlike other subtypes, it shows no short-exon bias. Surprisingly, however, in basal breast cancer, RIF1 Exon 31 isnot consistently excluded, which may impact prognosis since RIF1-Long protects against replication stress.  \nKeywords: breast cancer; RNA splicing; TCGA  \n1. Introduction  \nGenome instability is closely intertwined with carcinogenesis, and tumours almost invariably show mutation or altered expression of genome maintenance factors that regulate DNA replication and repair [1,2] . Consistently, prolonged DNA replication stress and associated DNA damage are important contributors to tumorigenesis. Cancer cells often experience elevated replication stress induced by DNA repair protein mutations, checkpoint inactivation, and rapid cell division. Many cancer therapies exploit this vulnerability, inducing irreparable DNA damage to eliminate cells with compromised genome maintenance pathways [3,4] .  \nMammalian RIF1 (Rap1 Interacting Factor 1) is a multifunctional protein with numerous roles in genome stability. RIF1 expression has been reported as upregulated across different tumour types, including breast, cervical, ovarian, and non-small cell lung cancers [5–8] . This upregulation has been correlated with enhanced tumour growth, migration, and cell survival following radio-and chemotherapy. The elevated expression of RIF1 within certain tumours may affect their vulnerability to specific DNA-damaging treatments,  \noffering a potential avenue for targeted therapeutic strategies [9] . It is therefore important to understand RIF1 expression changes in cancer.  \nRIF1 serves to r","cbCaiokpi1RINI2s","https://ap.wps.com/l/cbCaiokpi1RINI2s","pdf",1369486,18,"English","# Abstract\n# Introduction","[{\"question\":\"What roles do RIF1-Long and RIF1-Short play in genome stability and replication stress?\",\"answer\":\"RIF1 variants differ in their ability to protect cells from DNA replication stress, with RIF1-Long providing stronger replication stress resistance. The RIF1-Short form is linked to reduced protection under replication stress conditions.\"},{\"question\":\"How does RIF1 splicing differ across breast cancer subtypes?\",\"answer\":\"Luminal A, Luminal B, and HER2-enriched cancers tend to exclude RIF1 Exon 31, favoring RIF1-Short and correlating with poorer clinical outcomes. Basal breast cancer shows exon exclusion but does not consistently exclude RIF1 Exon 31.\"},{\"question\":\"What dataset and sample design were used to evaluate RIF1 expression and splicing?\",\"answer\":\"The analysis uses matched normal and tumor data from The Cancer Genome Atlas (TCGA), alongside cancer cell line experiments under replication stress. This design supports comparison of differential expression and splicing patterns.\"}]","Dysregulated Alternative Splicing in Breast Cancer Subtypes of RIF1 and Other Transcripts | PDF",1790184410,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/549970a01953214cce8ad6288a2e721c.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc14b14536bb16826f87e5849dc0b818.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba09be631205fc4c055b1ff26b603eae.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87dbc71ff6b2e7146110bc2267c56db5.webp",980,1385]